Filtration Designs Remove Processing Bottlenecks for High-Yield Biotech Drugs - Deep pleats and asymmetric pores increase the capacity and lifetime of a cartridge - BioPharm International

ADVERTISEMENT

Filtration Designs Remove Processing Bottlenecks for High-Yield Biotech Drugs
Deep pleats and asymmetric pores increase the capacity and lifetime of a cartridge


BioPharm International



Table 2. IgG Transmission
In some cases, where low concentrations of proteins or preservatives are in the fluid, there may be a loss in product yield if the filter membrane adsorbs significant amonts of product . At high component concentrations this is not a concern, but this is especially critical where a desired component is present in very low concentration. The effluent should be tested to ensure that the amount of loss is acceptable.


Table 3. Area per 10-inch cartridge
Here is a test run example. IgG protein transmission was measured to demonstrate differences in protein adsorption among membrane types. Each disc was challenged with 60 mL protein solution at 100 μg/mL concentration. Filtrate was collected in 1 mL aliquots for the first 10 mL followed by 5 mL aliquots to a total throughput of 60 mL. Data in Table 2 indicate that protein binding occurs within the first 10 mL passed through each membrane disc. After the first 10 mL, the effluent contains protein at the same concentration as the influent solution. PES and PVDF are generally low adsorptive materials. However, nylon bound 20 times more protein than PES in the first 10 mL. Extrapolating to production scale; this may affect product yield.

Lifetime is a Function of Construction

New filter designs have faster flow rates, smaller filter systems, improved microorganism and particle retention, and longer service life. These benefits translate into significant cost and time savings for drug manufacturers. Advances in the speed, size, and performance of new generation membrane filters are perhaps most critical because membrane technology is used in a broad range of applications. Lifetime (throughput) and flowrate at process scale are highly influenced by the structure of the membrane.


Figure 2. Cross section of high-area asymmetric filter cartridge showing retained contaminant
When flowrate is the main driver, new high-flow sterilizing-grade filters feature a serial layer construction where the upstream layer is an asymmetric, high porosity PES membrane over the final sterilizing-grade layer. This PES filter offers exceptionally high flows at a processing rate of 17 L/min at 100-mbar differential pressure (916;P), and is compatible with fluids across a wide pH range, from buffers to numerous biological fluids.


Figure 3. Upstream side of prefilter final filter layers showing clean membrane due to effective prefiltration
When lifetime is the main driver, a high-capacity sterilizing-grade filter offers users an innovative hybrid technology by fitting a finer grade of asymmetric PES membrane over a PVDF membrane. This membrane combination enables high dirt-holding capacities and the flexibility for either wet or dry steaming. Because autoclaving or steam-in-place procedures can take place in either wet or dry conditions, this flexibility accommodates different manufacturing specifications. The high-capacity hybrid filter offers competitive flow rates at 10 L/min at 100-mbar ΔP; in addition it offers the high throughput required in the filtration of high protein biotech solutions.

Asymmetric Prefilter Construction Improves Capacity


Figure 4. A unique folding pattern in a new filter design increases filter area
A technology that has contributed significantly to the performance of new generation membrane filters is an asymmetric membrane structure that offers a 3 to 1 average pore size gradient through the depth of the membrane, resulting in higher porosity and dirt holding capacity. This pore size gradient (Figure 1) enables larger particles to be captured in the outer portion of the filter, while the sterilizing layer provides high efficiency removal of smaller microorganisms.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

New Tax Rules May Deter Future Pharma M&A
October 1, 2014
NIH Seeks to Improve Vaccine Response with New Adjuvants
September 30, 2014
New Report Details Players and Pipelines in the Biosimilar Space
September 30, 2014
Baxter International Plans to Open R&D Center for Baxalta
September 30, 2014
FDA Releases First-Ever Purple Book for Biosimilar Characterization
September 26, 2014
Author Guidelines
Source: BioPharm International,
Click here